Filtered By:
Therapy: Chemotherapy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 93387 results found since Jan 2013.
Primary cutaneous B-cell lymphomas: Part II. Therapy and future directions
The choice of therapy for primary cutaneous B-cell lymphoma (PCBCL) relies on correct histopathologic classification and the exclusion of systemic disease. In part II of this continuing medical education article, we will review the available therapies for the different types of PCBCL. Primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL) are indolent tumors with an excellent prognosis. They are managed similarly with local therapy, such as radiotherapy or surgical excision, for isolated disease and observation for asymptomatic multifocal presentations. Relapses are common i...
Source: Journal of the American Academy of Dermatology - August 22, 2013 Category: Dermatology Authors: Andrea Luísa Suárez, Christiane Querfeld, Steven Horwitz, Melissa Pulitzer, Alison Moskowitz, Patricia L. Myskowski Tags: Continuing Medical Education Source Type: research
Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
Whereas benign pheochromocytomas and paragangliomas are often successfully cured by surgical resection, treatment of metastatic disease can be challenging in terms of both disease control and symptom control. Fortunately, several options are available, including chemotherapy, radiation therapy, and surgical debulking. Radiolabeled metaiodobenzylguanidine (MIBG) and somatostatin receptor imaging have laid the groundwork for use of these radiopharmaceuticals as theranostic agents. 131I-MIBG therapy of neuroendocrine tumors has a long history, and the recent approval of high-specific-activity 131I-MIBG for metastatic or inope...
Source: Journal of Nuclear Medicine - September 2, 2021 Category: Nuclear Medicine Authors: Carrasquillo, J. A., Chen, C. C., Jha, A., Pacak, K., Pryma, D. A., Lin, F. I. Tags: Continuing Education Source Type: research
PER Events, LLC, Acquires Chemotherapy Foundation Symposium, Grows...
Addition of renowned multi-tumor cancer conference augments PER’s robust portfolio of continuing medical education offerings in oncology.(PRWeb May 20, 2015)Read the full story at http://www.prweb.com/releases/PER/CFSymposium/prweb12667738.htm
Source: PRWeb: Medical Pharmaceuticals - May 21, 2015 Category: Pharmaceuticals Source Type: news
The model of care at a leading medical cannabis clinic in Canada
Complement Ther Med. 2021 May 27:102740. doi: 10.1016/j.ctim.2021.102740. Online ahead of print.ABSTRACTMedical cannabis access has been legalized in more than 30 countries worldwide and popularity among patients is increasing rapidly. Cannabinoid-based treatments have been shown to be beneficial for several symptoms such as chemotherapy-induced nausea and vomiting, spasticity, chronic pain, intractable seizures and insomnia, yet high-quality clinical trials are still limited. As millions of patients now have legal access to medical cannabis, little information is available about the development of best clinical practices ...
Source: Complementary Therapies in Medicine - May 30, 2021 Category: Complementary Medicine Authors: Erin Prosk Maria Fernanda Arboleda Lucile Rapin Cynthia El Hage Michael Dworkind Source Type: research
Abstract P1-10-16: Improving provider adherence to breast cancer care quality metrics: Use of a novel care planning tool
Conclusions: The On Q CPS, a care planning software tool, has the potential to both improve provider adherence to NQS and allow institutions an easy and accessible way to document that adherence.Citation Format: Hathaway A, Halilova K, Gaguski ME, Thomas K, Dudley WN, Stricker CT, Hammelef KJ, Panzer SL, Rocque GB. Improving provider adherence to breast cancer care quality metrics: Use of a novel care planning tool. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-16.
Source: Cancer Research - February 18, 2016 Category: Cancer & Oncology Authors: Hathaway, A., Halilova, K., Gaguski, M., Thomas, K., Dudley, W., Stricker, C., Hammelef, K., Panzer, S., Rocque, G. Tags: Poster Session Abstracts Source Type: research
Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer
ConclusionsThis study identified appreciable discrepancies between oncologists ’ recommendations and standard evidence-based guidelines. Well-designed CME programs may help to bridge the educational gaps identified and improve adherence to practice guidelines.
Source: Journal of Gastrointestinal Cancer - November 27, 2017 Category: Cancer & Oncology Source Type: research
Nurses' knowledge and education about oral care of cancer patients undergoing chemotherapy and radiation therapy
Conclusion: Lack of knowledge suggest the need to develop and implement continuing nursing education programs on oral care specifically for patients receiving cancer treatments, for improving knowledge of staff nurses' in order to render comprehensive care to the patients. This study also recommends the importance of inclusion of cancer patient specific oral care in the curriculum which can enhance competency of the qualified nurses in cancer wards.
Source: Indian Journal of Palliative Care - May 6, 2015 Category: Palliative Care Authors: Radhika R PaiRavikiran Ongole Source Type: research
Addressing Challenges in Living with AML: Impact of Video-Based Patient Education on Knowledge and Behavior
Conclusions: Education on AML specifically catered to patients and their families can yield immediate and sustained gains in knowledge and behavior, which may improve their adherence to treatment, quality of life, and patient outcomes.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Roc, A. C., Steensma, D. P., Rajotte, M., Turell, W. Tags: 904. Outcomes Research-Malignant Conditions: Poster III Source Type: research
Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder
Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants (SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from asymptomatic viremia through infectious mononucleosis to posttransplant lymphoproliferative disorder (PTLD). EBV disease and its associated PTLD is more frequently seen when primary EBV infection occurs after transplant, a common scenario in pediatric SOT recipients. Intensity of immunosuppressive therapies also influences the risk for PTLD. The use of EBV viral load monitoring facilitates the diagnosis and management of EBV/PTLD as well as bein...
Source: American Journal of Transplantation - January 24, 2013 Category: Transplant Surgery Authors: M. Green, M. G. Michaels Tags: Continuing Medical Education Source Type: research
Human Herpesviruses 6, 7 and 8 in Solid Organ Transplant Recipients
Human herpesviruses (HHV) 6 and 7 are ubiquitous infections that reactivate commonly in transplant recipients. However, clinical diseases due to these viruses are reported only in 1% of solid organ transplant recipients. Fever, rash and bone marrow suppression are the most common manifestations, but symptoms of tissue invasive disease may be observed. Treatment of HHV‐6 and HHV‐7 disease includes antiviral therapy and cautious reduction in immunosuppression. HHV‐8 is an oncogenic gamma‐herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in transplant recipients. Nonmalignant...
Source: American Journal of Transplantation - January 24, 2013 Category: Transplant Surgery Authors: R. R. Razonable Tags: Continuing Medical Education Source Type: research
Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
Disease OverviewImmunoglobulin (Ig) light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of Ig light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma.
DiagnosisTissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in ...
Source: American Journal of Hematology - April 18, 2013 Category: Hematology Authors: Morie A. Gertz Tags: A Continuing Medical Education Series Source Type: research
Mantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Disease OverviewMantle cell lymphoma (MCL) is a non‐Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood, and bone marrow with a short remission duration to standard therapies and a median overall survival of 4–5 years.
DiagnosisDiagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. A chromosomal translocation t(11:14) is the molecular hallmark of MCL, resulting in the overexpression of cyclin D1. Cyclin D1 is detected by immunohistochemistry in 98% of cases. The absence of SOX‐11 or a low Ki‐67 may corre...
Source: American Journal of Hematology - November 22, 2013 Category: Hematology Authors: Julie M. Vose Tags: Annual Clinical Updates in Hematological Malignancies: A Continuing Medical Education Series Source Type: research
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome) Part II. Prognosis, management, and future directions
Both mycosis fungoides (MF) and Sézary syndrome (SS) have a chronic, relapsing course, with patients frequently undergoing multiple, consecutive therapies. Treatment is aimed at the clearance of skin disease, the minimization of recurrence, the prevention of disease progression, and the preservation of quality of life. Other important considerations are symptom severity, including pruritus and patient age/comorbidities. In general, for limited patch and plaque disease, patients have excellent prognosis on ≥1 topical formulations, including topical corticosteroids and nitrogen mustard, with widespread patch/plaque diseas...
Source: Journal of the American Academy of Dermatology - January 16, 2014 Category: Dermatology Authors: Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, Alison Moskowitz, Christiane Querfeld Tags: Continuing Medical Education Source Type: research
Hodgkin lymphoma: 2014 update on diagnosis, risk‐stratification, and management
Disease overview: Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 9,200 new patients annually and representing approximately 11.5% of all lymphomas in the United States.
Diagnosis: HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte‐predominant HL. Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte‐rich HL are subgroups under the designation of classical HL.
Risk stratification: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therap...
Source: American Journal of Hematology - June 20, 2014 Category: Hematology Authors: Stephen M. Ansell Tags: A Continuing Medical Education Series Source Type: research
